{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=72", "query": { "intervention": "pembrolizumab", "page": 72 }, "page_size": 10 }, "pagination": { "page": 72, "page_size": 10, "total_count": 1852, "total_pages": 186, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=73&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=71&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T15:30:35.342Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02376699", "title": "Safety Study of SEA-CD40 in Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Squamous Cell", "Hodgkin Disease", "Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Melanoma", "Neoplasm Metastasis", "Neoplasms, Head and Neck", "Neoplasms, Squamous Cell", "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Cancer Metastatic", "Non-small Cell Carcinoma", "Squamous Cell Cancer", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Neoplasm", "Lymphoma, Non-Hodgkin", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Intravenous (IV) SEA-CD40", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Subcutaneous (SC) SEA-CD40", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2015-02-28", "completion_date": "2023-04-14", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02376699" }, { "nct_id": "NCT06096844", "title": "Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 304, "start_date": "2024-07-19", "completion_date": "2039-04-01", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 330, "location_summary": "Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 259 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06096844" }, { "nct_id": "NCT05740501", "title": "Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Non-Small Cell Carcinoma", "Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-04-26", "completion_date": "2020-01-03", "has_results": false, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05740501" }, { "nct_id": "NCT06103864", "title": "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 625, "start_date": "2023-11-23", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 66, "location_summary": "Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06103864" }, { "nct_id": "NCT04069273", "title": "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "GastroEsophageal Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab Monotherapy", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry H Yoon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-12-01", "completion_date": "2027-12-10", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Milwaukee, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04069273" }, { "nct_id": "NCT07762703", "title": "Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple-Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "BreakVax", "type": "DRUG" }, { "name": "Ipilimumab 2.5 mg", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Standard-of-care chemotherapy", "type": "DRUG" }, { "name": "Losartan and aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BreakBio Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 10, "start_date": "2026-09", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07762703" }, { "nct_id": "NCT03657641", "title": "Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2019-06-21", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Tampa, Florida", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657641" }, { "nct_id": "NCT03632941", "title": "A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2+ Breast Cancer" ], "interventions": [ { "name": "VRP-HER2", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Herbert Lyerly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2019-03-01", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03632941" }, { "nct_id": "NCT06669572", "title": "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell", "Anorectal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-07-11", "completion_date": "2029-03-26", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06669572" }, { "nct_id": "NCT06504394", "title": "A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma Recurrent", "Classical Hodgkin Lymphoma Refractory", "Primary Mediastinal Large B-cell Lymphoma Recurrent", "Primary Mediastinal Large B-cell Lymphoma Refractory" ], "interventions": [ { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-10-14", "completion_date": "2028-11-08", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-11-07T15:30:35.342Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Waukee, Iowa • Las Vegas, Nevada + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Waukee", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Westbury", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06504394" } ] }